Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 5Active not recruiting 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Peritoneal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × soluble LAG-3 protein, human × Clear all
NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Immutep S.A.S.

Phase 3 Active not recruiting
756 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03252938 2026-02-19

INSIGHT

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 1 Active not recruiting
83 enrolled
GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Immutep S.A.S.

Phase 2/3 Active not recruiting
849 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡